PL2623507T3 - Pochodna kwasu morfolinonukleinowego - Google Patents
Pochodna kwasu morfolinonukleinowegoInfo
- Publication number
- PL2623507T3 PL2623507T3 PL11829283T PL11829283T PL2623507T3 PL 2623507 T3 PL2623507 T3 PL 2623507T3 PL 11829283 T PL11829283 T PL 11829283T PL 11829283 T PL11829283 T PL 11829283T PL 2623507 T3 PL2623507 T3 PL 2623507T3
- Authority
- PL
- Poland
- Prior art keywords
- nucleic acid
- acid derivative
- morpholino nucleic
- morpholino
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010220865 | 2010-09-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2623507T3 true PL2623507T3 (pl) | 2017-03-31 |
Family
ID=45893168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11829283T PL2623507T3 (pl) | 2010-09-30 | 2011-09-29 | Pochodna kwasu morfolinonukleinowego |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8969551B2 (pl) |
| EP (1) | EP2623507B1 (pl) |
| JP (1) | JP5831455B2 (pl) |
| KR (1) | KR101764462B1 (pl) |
| CN (1) | CN103154009B (pl) |
| CA (1) | CA2813183C (pl) |
| CY (1) | CY1118435T1 (pl) |
| DK (1) | DK2623507T3 (pl) |
| ES (1) | ES2607603T3 (pl) |
| HR (1) | HRP20170028T1 (pl) |
| HU (1) | HUE030292T2 (pl) |
| LT (1) | LT2623507T (pl) |
| PL (1) | PL2623507T3 (pl) |
| PT (1) | PT2623507T (pl) |
| RS (1) | RS55610B1 (pl) |
| SI (1) | SI2623507T1 (pl) |
| SM (2) | SMT201700038T1 (pl) |
| WO (1) | WO2012043730A1 (pl) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2500430B1 (en) | 2004-06-28 | 2017-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
| ES2852549T3 (es) | 2005-02-09 | 2021-09-13 | Sarepta Therapeutics Inc | Composición antisentido para tratamiento de la atrofia muscular |
| KR20250016146A (ko) | 2008-10-24 | 2025-02-03 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Dmd를 위한 다중 엑손 스키핑 조성물 |
| KR102239374B1 (ko) | 2009-11-12 | 2021-04-14 | 더 유니버시티 오브 웨스턴 오스트레일리아 | 안티센스 분자 및 이를 이용한 질환 치료방법 |
| KR20200133284A (ko) * | 2010-05-28 | 2020-11-26 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체 |
| WO2012031243A2 (en) | 2010-09-03 | 2012-03-08 | Avi Biopharma, Inc. | dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS |
| US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
| KR102142689B1 (ko) | 2011-11-18 | 2020-08-10 | 사렙타 쎄러퓨틱스, 인코퍼레이티드 | 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트 |
| CA2868174A1 (en) | 2012-03-20 | 2013-09-26 | Sarepta Therapeutics, Inc. | Boronic acid conjugates of oligonucleotide analogues |
| CN102702265A (zh) * | 2012-05-14 | 2012-10-03 | 天津特安化学科技有限公司 | 一种固相合成磷酰二胺吗啉代寡核苷酸及方法 |
| CN105378081B (zh) | 2013-03-14 | 2019-06-14 | 萨勒普塔医疗公司 | 用于治疗肌营养不良的外显子跳跃组合物 |
| EP3662912B1 (en) | 2013-03-15 | 2025-12-03 | Sarepta Therapeutics, Inc. | Improved dosages of eteplirsen for treating duchenne muscular dystrophy |
| CN105228999B (zh) | 2013-05-24 | 2021-03-02 | 味之素株式会社 | 吗啉代寡核苷酸的制备方法 |
| AU2014317961B2 (en) | 2013-09-05 | 2020-07-30 | Murdoch University | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
| US9790495B2 (en) | 2014-05-16 | 2017-10-17 | Oregon State University | Antisense antibacterial compounds and methods |
| AU2015264449B2 (en) | 2014-05-19 | 2022-05-05 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
| WO2016060135A1 (ja) * | 2014-10-14 | 2016-04-21 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
| JP6994941B2 (ja) * | 2014-12-31 | 2022-02-04 | オレゴン ステート ユニバーシティ | アンチセンス抗細菌性化合物および方法 |
| MA41795A (fr) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | Exclusion d'un exon induite par des composés antisens dans la myostatine |
| HRP20231431T1 (hr) | 2015-05-19 | 2024-03-01 | Sarepta Therapeutics, Inc. | Peptidno oligonukleotidni konjugati |
| US10849917B2 (en) | 2015-06-01 | 2020-12-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type VII collagen |
| US11020417B2 (en) | 2015-06-04 | 2021-06-01 | Sarepta Therapeutics, Inc | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
| HRP20220129T1 (hr) | 2015-08-05 | 2022-04-15 | Eisai R&D Management Co., Ltd. | Postupak za pripremu uglavnom dijastereomerno čistog fosforodiamidatnog oligomera, fosforodiamidatni oligomer dobiven takvim postupkom i farmaceutski pripravak koji sadrži takav fosforodiamidatni oligomer |
| WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
| CA3006748A1 (en) * | 2015-12-15 | 2017-06-22 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
| EP3394262B1 (en) | 2015-12-23 | 2024-08-28 | Oregon State University | Antisense antibacterial compounds and methods |
| CA3010084A1 (en) | 2015-12-23 | 2017-06-29 | Oregon State University | Antisense antibacterial compounds and methods |
| BR112018071477A2 (pt) | 2016-04-18 | 2019-02-19 | Sarepta Therapeutics, Inc. | oligômeros antisenso e métodos de utilização dos mesmos para tratamento de doenças associadas com o gene da alfa-glicosidase ácida |
| MX2018013157A (es) | 2016-04-29 | 2019-05-23 | Sarepta Therapeutics Inc | Analogos de oligonucleotidos dirigidos a lmna humana. |
| SG10202101836TA (en) | 2016-05-24 | 2021-03-30 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
| EP3464305B1 (en) | 2016-05-24 | 2024-08-21 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
| US20190275072A1 (en) | 2016-05-24 | 2019-09-12 | Sarepta Therapeutics, Inc. | Pharmaceutical compositions comprising eteplirsen |
| HRP20240583T1 (hr) | 2016-05-24 | 2024-07-19 | Sarepta Therapeutics, Inc. | Postupci za pripremu fosforodiamidat morfolino oligomera |
| US10947533B2 (en) | 2016-05-24 | 2021-03-16 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| CA3024153A1 (en) | 2016-06-30 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
| CN116804031A (zh) * | 2016-09-20 | 2023-09-26 | 科罗拉多州立大学董事会法人团体 | 使用亚磷酰胺化学法合成主链修饰的吗啉代寡核苷酸和嵌合体 |
| AU2018256435B2 (en) | 2017-04-20 | 2025-03-13 | Atyr Pharma, Inc. | Compositions and methods for treating lung inflammation |
| EP3672601B1 (en) * | 2017-09-25 | 2023-09-13 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers via fast-flow synthesis |
| JP7394753B2 (ja) | 2017-10-18 | 2023-12-08 | サレプタ セラピューティクス， インコーポレイテッド | アンチセンスオリゴマー化合物 |
| SG11202011094PA (en) | 2018-05-10 | 2020-12-30 | Nippon Shinyaku Co Ltd | Method for preparing oligonucleic acid compound |
| WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
| EP4059943A4 (en) | 2019-11-13 | 2024-01-31 | Nippon Shinyaku Co., Ltd. | METHOD FOR PRODUCING OLIGONUCLEIC ACID COMPOUND |
| US20230018780A1 (en) * | 2019-11-13 | 2023-01-19 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| KR20230035623A (ko) * | 2020-07-10 | 2023-03-14 | 창저우 신더올 파마슈티컬스 컴퍼니 리미티드 | 올리고뉴클레오티드의 제조 방법 |
| CN117279926A (zh) * | 2021-04-28 | 2023-12-22 | 日本新药株式会社 | 低聚核酸化合物的制造方法 |
| MX2023012559A (es) | 2021-04-30 | 2023-12-15 | Sarepta Therapeutics Inc | Métodos de tratamiento para la distrofia muscular. |
| US12378267B2 (en) | 2021-06-17 | 2025-08-05 | Entrada Therapeutics, Inc. | Synthesis of FMOC-protected morpholino monomers and oligomers |
| JP2024539223A (ja) | 2021-10-22 | 2024-10-28 | サレプタ セラピューティクス， インコーポレイテッド | 末梢ミエリンタンパク質２２関連疾患の処置のためのモルフォリノオリゴマー |
| AU2022424485A1 (en) * | 2021-12-27 | 2024-07-11 | Nippon Shinyaku Co., Ltd. | Method for producing oligonucleic acid compound |
| WO2023167908A1 (en) * | 2022-03-01 | 2023-09-07 | Eisai R&D Management Co., Ltd. | Bis-protected, activated guanine monomers |
| AU2023235302A1 (en) | 2022-03-17 | 2024-10-24 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
| US20250289851A1 (en) | 2022-04-22 | 2025-09-18 | Entrada Therapeutics, Inc. | Cyclic peptides for delivering therapeutics |
| WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2069869C (en) | 1989-12-20 | 1995-12-19 | James E. Summerton | Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages |
| JP2005255530A (ja) * | 2004-03-09 | 2005-09-22 | Japan Science & Technology Agency | ２−チオウリジン誘導体 |
| PL2735568T3 (pl) * | 2006-05-10 | 2018-02-28 | Sarepta Therapeutics, Inc. | Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami |
| US8076476B2 (en) * | 2007-11-15 | 2011-12-13 | Avi Biopharma, Inc. | Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits |
| ES2479393T3 (es) * | 2007-11-15 | 2014-07-24 | Sarepta Therapeutics, Inc. | Método de síntesis de oligómeros de morfolino |
-
2011
- 2011-09-29 HR HRP20170028TT patent/HRP20170028T1/hr unknown
- 2011-09-29 HU HUE11829283A patent/HUE030292T2/en unknown
- 2011-09-29 SI SI201131069A patent/SI2623507T1/sl unknown
- 2011-09-29 DK DK11829283.8T patent/DK2623507T3/da active
- 2011-09-29 KR KR1020137011017A patent/KR101764462B1/ko active Active
- 2011-09-29 CA CA2813183A patent/CA2813183C/en active Active
- 2011-09-29 RS RS20170057A patent/RS55610B1/sr unknown
- 2011-09-29 US US13/876,194 patent/US8969551B2/en active Active
- 2011-09-29 SM SM20170038T patent/SMT201700038T1/it unknown
- 2011-09-29 ES ES11829283.8T patent/ES2607603T3/es active Active
- 2011-09-29 EP EP11829283.8A patent/EP2623507B1/en active Active
- 2011-09-29 JP JP2012536551A patent/JP5831455B2/ja active Active
- 2011-09-29 LT LTEP11829283.8T patent/LT2623507T/lt unknown
- 2011-09-29 PT PT118292838T patent/PT2623507T/pt unknown
- 2011-09-29 CN CN201180047487.3A patent/CN103154009B/zh active Active
- 2011-09-29 WO PCT/JP2011/072407 patent/WO2012043730A1/ja not_active Ceased
- 2011-09-29 PL PL11829283T patent/PL2623507T3/pl unknown
-
2017
- 2017-01-10 CY CY20171100027T patent/CY1118435T1/el unknown
- 2017-01-19 SM SM201700038T patent/SMT201700038B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201700038B (it) | 2017-03-08 |
| HUE030292T2 (en) | 2017-04-28 |
| US8969551B2 (en) | 2015-03-03 |
| WO2012043730A1 (ja) | 2012-04-05 |
| SI2623507T1 (sl) | 2017-04-26 |
| CY1118435T1 (el) | 2017-06-28 |
| KR20130143045A (ko) | 2013-12-30 |
| HRP20170028T1 (hr) | 2017-03-24 |
| EP2623507A1 (en) | 2013-08-07 |
| CN103154009B (zh) | 2015-06-10 |
| PT2623507T (pt) | 2016-12-23 |
| CN103154009A (zh) | 2013-06-12 |
| ES2607603T3 (es) | 2017-04-03 |
| CA2813183A1 (en) | 2012-04-05 |
| JP5831455B2 (ja) | 2015-12-09 |
| JPWO2012043730A1 (ja) | 2014-02-24 |
| KR101764462B1 (ko) | 2017-08-02 |
| CA2813183C (en) | 2017-09-19 |
| SMT201700038T1 (it) | 2017-03-08 |
| EP2623507A4 (en) | 2014-03-19 |
| LT2623507T (lt) | 2017-01-25 |
| DK2623507T3 (da) | 2017-01-02 |
| RS55610B1 (sr) | 2017-06-30 |
| US20130197220A1 (en) | 2013-08-01 |
| EP2623507B1 (en) | 2016-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2623507T (lt) | Morfolino nukleorūgšties darinys | |
| GB2494239B (en) | Nucleic acid amplification | |
| SI2612917T1 (sl) | Protismiselna nukleinska kislina | |
| DK2922554T3 (en) | Terminalt modificeret rna | |
| IL231983B (en) | Dna containing tricyclo-phosphorothioate | |
| SG11201406717RA (en) | Nucleic acid amplification | |
| GB201204407D0 (en) | Nucleic acid molecule | |
| LT2993232T (lt) | Nukleorūgščių gavimo būdas | |
| IL223642A (en) | Inorganic elements to enhance gene expression | |
| ZA201304998B (en) | Dna expression construct | |
| ZA201206793B (en) | Nucleic acid complexes | |
| GB2479833B (en) | Modified nucleotides | |
| ZA201400918B (en) | Pyrrolidine-3-ylacetic acid derivative | |
| GB201120989D0 (en) | Genetic test | |
| SI2628733T1 (sl) | Derivati acilbenzena | |
| EP2594592A4 (en) | COMPLEX (NUCLEIC ACID) -POLYSACCHARIDE | |
| GB201107286D0 (en) | Nucleic acid preparation | |
| GB201001940D0 (en) | Nucleic acid isolation | |
| GB201105387D0 (en) | Nucleic acid probes | |
| GB201009654D0 (en) | Nucleic acid methyltransferase | |
| AU2011902654A0 (en) | Nucleic acid complex | |
| GB201014572D0 (en) | Genetic tests | |
| GB201004862D0 (en) | DNA amplification | |
| GB201115254D0 (en) | Genetic test | |
| GB201021720D0 (en) | Gene variant |